COMPANY

Tenax Therapeutics

HQ: Chapel Hill, NC (US office) source · tenaxthera.com ↗ · Southeast

Location: Chapel Hill, NC (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Pulmonary Hypertension Associated With HFpEF Heart Failure With Normal Ejection Fraction Traumatic Brain Injury Pulmonary Hypertension Hypertension Pulmonary Secondary Heart Failure Right Sided Heart Failure With Normal Ejection Fraction Right Sided Heart Failure Coronary Artery Bypass Grafting Mitral Valve Surgery Low Cardiac Output Syndrome Heart Decompensation TNX-103 Levosimendan Oxycyte

$25.0MRaised (2 yrs)9Trials (company is sponsor)

Timeline

Mar 13, 2026 Trial start Phase 3: Long-Term Open-Label Extension Study of Oral Levosimendan source ↗
Mar 3, 2026 Trial start Phase 3: LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 source ↗
Mar 5, 2025 Raise Private placement: $25M (total, as published), announced Mar 5, 2025. Source: SEC filing. source ↗
Jan 10, 2024 Trial start Phase 3: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF source ↗
Apr 9, 2019 Trial start Phase 2: Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients source ↗
Nov 14, 2018 Trial start Phase 2: Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF source ↗
2014-07 Trial start Phase 3: Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass source ↗
2009-10 Trial start Phase 2: Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI) source ↗
2005-09 Trial start Phase 2: Study of Oxycyte in Severe Closed Head Injury source ↗

Upcoming milestones

Jun 30, 2028 (ESTIMATED) · Phase 3 · LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 · NCT07288398
2029-03 (ESTIMATED) · Phase 3 · Long-Term Open-Label Extension Study of Oral Levosimendan · NCT07436689

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $25.0M. Last 2 years.

Mar 5, 2025 Private placement: $25M (total, as published), announced Mar 5, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT07436689	Long-Term Open-Label Extension Study of Oral Levosimendan	Phase 3	Enrolling by invitation	Mar 13, 2026	2029-03 (estimated)
NCT07288398	LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2	Phase 3	Recruiting	Mar 3, 2026	Jun 30, 2028 (estimated)
NCT05983250	LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF	Phase 3	Active, not recruiting	Jan 10, 2024	Jun 30, 2026 (actual)
NCT03624010	Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients	Phase 2	Completed	Apr 9, 2019	Apr 25, 2023 (actual)
NCT00174980	Study of Oxycyte in Severe Closed Head Injury	Phase 2	Terminated	2005-09	2008-03 (actual)
NCT03541603	Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF	Phase 2	Completed	Nov 14, 2018	Apr 7, 2020 (actual)
NCT02025621	Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass	Phase 3	Completed	2014-07	2016-11 (actual)
NCT02973620	Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure	Not listed	No longer available	Not listed	Not listed
NCT00908063	Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI)	Phase 2	Terminated	2009-10	2014-09 (actual)